Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2021 Financial Results
10-Aug-2021 10:30:00 | Yahoo Sports
Follow-up Cullinan Pearl data from Phase 1 portion of ongoing trial showed increased disease control rate (DCR) of 92% in the 100mg dose cohort IND clearance of two immuno-oncology pipeline programs, Cullinan MICA and Cullinan Florentine, with clinical trial starts for each program expected in 2H 2021 Strong balance sheet with cash and investments of $456.3 million as of June 30, 2021 CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), an oncology company
Read More